Cyclophosphamide
Myeloid Sarcoma
St. Jude Children's Research HospitalSmall moleculePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 89/ 100
Competitive context
24 Active assets in the Myeloid Sarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid Kura Oncology, Inc. | Phase 3 | BB |
Mitoxantrone Ruijin Hospital | Phase 3 | BB |
Daunorubicin Kura Oncology, Inc. | Phase 3 | BB |
ETOPOSIDE St. Jude Children's Research Hospital | Phase 3 | BB |
Venetoclax Ruijin Hospital | Phase 2 | BB |
View all 32 →
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →